What Is MOTS-c? The Mitochondrial-Derived Peptide Explained

By DoseGauge Editorial · Updated 2026-06-14 · 5 min read

MOTS-c is a 16-amino-acid peptide encoded by the 12S rRNA region of mitochondrial DNA, one of a small class of molecules known as mitochondrial-derived peptides. It has been studied as a regulator of metabolic homeostasis and insulin sensitivity, with research describing mechanisms such as AMPK activation. It is a research peptide, not approved by the FDA for any use, and the evidence base is largely preclinical: most of what is known comes from cell-culture and animal studies, with very limited human data. This page explains what MOTS-c is and how it is reported to work. It is informational and educational only, not medical advice, and it does not recommend MOTS-c or any dose.

What MOTS-c is

MOTS-c is a short peptide that the body encodes inside its own mitochondria. It is 16 amino acids long and is read from the 12S rRNA region of the mitochondrial genome through a short open reading frame, rather than from the nuclear DNA that encodes most proteins (Mohtashami et al., 2022; Wan et al., 2023).

That origin is what defines its class. MOTS-c belongs to a small group called mitochondrial-derived peptides, molecules encoded within mitochondrial DNA rather than the cell nucleus. The cited reviews note that the MOTS-c sequence is highly conserved across mammalian species, which is one reason researchers have taken interest in it (Mohtashami et al., 2022). It occurs naturally in the body; the injectable material sold for research is a synthetic version of that same peptide.

How MOTS-c works

MOTS-c has been studied as a regulator of metabolic homeostasis and insulin sensitivity. The reviews describe its main signaling route through the folate-AICAR-AMPK pathway, with AMPK activation as a central step (Wan et al., 2023). AMPK is a cellular energy sensor, and its activation is linked in the reviews to effects on metabolic homeostasis, insulin response, fat accumulation, and exercise-related adaptation (Wan et al., 2023).

The reviews also describe MOTS-c moving into the cell nucleus under metabolic stress, where it influences the expression of genes involved in the cell's stress response (Mohtashami et al., 2022). In cell and animal work, these mechanisms are tied to improved glucose utilization and insulin sensitivity (Wan et al., 2023). It is worth being precise: these are the mechanisms the reviews report from preclinical research, not established outcomes in people.

What the research has looked at

The cited reviews summarize a research base that spans metabolism, cellular stress, exercise capacity, and aging. In animal models, MOTS-c has been studied for its effects on glucose handling and insulin sensitivity, including work in high-fat-diet models (Wan et al., 2023). The reviews also discuss roles in the stress response and in exercise, noting that exercise can upregulate MOTS-c and that the peptide has been associated with physical performance in aged mice (Wan et al., 2023).

A recurring theme is aging and age-related disease. One review reports that MOTS-c levels measured in older adults were lower than in younger adults, which is part of why it has been examined in the context of aging (Mohtashami et al., 2022). The important caveat across all of this is the same: most findings come from cell culture and animal models. Human data are limited, so these are research observations rather than demonstrated human effects.

Regulatory status and evidence

MOTS-c is a research peptide. It is not approved by the FDA for any indication, and there is no established clinical dose or approved use in humans. Human pharmacokinetic data are limited, and no validated human plasma half-life has been published in the peer-reviewed literature.

That status is the context for everything above. The mechanisms and effects described here come from preclinical research, and they do not amount to regulatory approval or to an established safety and efficacy profile in people. This page describes what MOTS-c is and how it is reported to work; it does not claim it is safe, effective, or appropriate for any purpose, and it does not recommend using it. Whether any research peptide is appropriate is a decision for a licensed clinician. For what the studies have examined in more detail, see mots-c benefits.

Frequently asked questions

What is MOTS-c used for?

MOTS-c is a research peptide studied for its role in metabolism and insulin sensitivity, with mechanisms such as AMPK activation described in the literature (Wan et al., 2023). The cited reviews also discuss roles in cellular stress, exercise capacity, and aging, largely in cell and animal models. It is not FDA-approved for any use, and this page does not recommend it for any purpose.

Is MOTS-c FDA-approved?

No. MOTS-c is not approved by the FDA for any indication. It is a research peptide, and the available evidence is largely preclinical, with very limited human clinical data. Consult a licensed clinician before using any research peptide.

What does MOTS-c do in the body?

In preclinical research, MOTS-c is described as acting mainly through the folate-AICAR-AMPK pathway, activating AMPK and influencing glucose utilization and insulin sensitivity (Wan et al., 2023). The reviews also report that it can move into the cell nucleus under metabolic stress and affect stress-response gene expression (Mohtashami et al., 2022). These are mechanisms reported from cell and animal studies, not established human outcomes.

Is MOTS-c a natural peptide?

MOTS-c occurs naturally in the body: it is encoded by the 12S rRNA region of mitochondrial DNA and is produced endogenously (Mohtashami et al., 2022; Wan et al., 2023). The injectable material sold for research, however, is a synthetic version of that peptide, and it is not FDA-approved for any use. So while the molecule itself is natural, the research product is a manufactured form.

Informational and educational only. Not medical advice. DoseGauge computes from the values you enter and does not recommend a dose. Talk to a licensed clinician before using any peptide or GLP-1 medication.